| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H19F4N7 |
| Molecular Weight | 445.4161 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C=C(N=C1C2CCN(CC2)C3=C4C=NNC4=NC=N3)C5=CC=C(F)C(=C5)C(F)(F)F
InChI
InChIKey=FYXRSVDHGLUMHB-UHFFFAOYSA-N
InChI=1S/C21H19F4N7/c1-31-10-17(13-2-3-16(22)15(8-13)21(23,24)25)29-19(31)12-4-6-32(7-5-12)20-14-9-28-30-18(14)26-11-27-20/h2-3,8-12H,4-7H2,1H3,(H,26,27,28,30)
LY2584702 is a potent, highly selective adenosine triphosphate (ATP) competitive inhibitor against p70 S6 kinase, a downstream component of the phosphatidylinositol-3-kinase signalling pathway which regulates cell proliferation and survival. LY2584702 underwent clinical trials against solid tumors both as a monotherapy and in combination with erlotinib or everolimus. No responses were observed for treatment as a single agent. LY2584702 was not well tolerated when administered with erlotinib, therefore this combination is not feasible. The combination with everolimus was better tolerated but yielded very limited clinical benefit.
Originator
Approval Year
Cmax
AUC
Doses
AEs
Sourcing
PubMed
Patents
ACTIVE MOIETY
